"Delivery of this report will take 1-3 days after purchase."
Global Public Health Partnering 2010-2016: Deal trends, players and financials provides comprehensive understanding and unprecedented access t- the public health partnering deals and agreements entered int- by the worlds leading healthcare companies
Global Public Health Partnering 2010 t- 2016 provides the full collection of Public Health disease deals signed between the world’s pharmaceutical and biotechnology companies since 2010.
Trends in Public Health partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Public Health partnering agreement structure
Public Health partnering contract documents
Top Public Health deals by value
Most active Public Health dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right t- license a licensor’s product or technology. More often these days these deals tend t- be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Public Health disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Public Health deals.
The report presents financial deal terms values for Public Health deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers t- analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Public Health dealmaking trends.
Chapter 1 provides an introduction t- the report.
Chapter 2 provides an overview of the trends in Public Health dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Public Health deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Public Health dealmakers, together with a full listing of deals t- which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access t- the contract.
Chapter 5 provides comprehensive access t- Public Health deals since 2010 where a deal contract is available, providing the user with direct access t- contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink t- an online version of the deal record contract document, providing easy access t- each contract document on demand.
Chapter 6 provides a comprehensive directory of all Public Health partnering deals by specific Public Health target announced since 2010. The chapter is organized by specific Public Health therapeutic target. Each deal title links via Weblink t- an online version of the deal record and where available, the contract document, providing easy access t- each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Public Health partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink t- an online version of the deal record and where available, the contract document, providing easy access t- each contract document on demand.
The report als- includes numerous tables and figures that illustrate the trends and activities in Public Health partnering and dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs t- know about partnering in the research, development and commercialization of Public Health technologies and products.
Global Public Health Partnering 2010 t- 2016 is intended t- provide the reader with an in-depth understanding and access t- Public Health trends and structure of deals entered int- by leading companies worldwide.
Global Public Health Partnering 2010 t- 2016 includes:
Trends in Public Health dealmaking in the biopharma industry since 2010
Analysis of Public Health deal structure
Access t- headline, upfront, milestone and royalty data
Access t- hundreds of Public Health deal contract documents
Comprehensive access t- over 3500 Public Health deal records
The leading Public Health deals by value since 2010
Most active Public Health dealmakers since 2010
In Global Public Health Partnering 2010 t- 2016, available deals and contracts are listed by:
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Specific therapy indication
Each deal title links via Weblink t- an online version of the deal record and where available, the contract document, providing easy access t- each contract document on demand.
The Global Public Health Partnering 2010-2016 report provides comprehensive access t- available deals and contract documents for over 200 public health deals. Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement t- the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Wh- is responsible for commercialization?
Wh- is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes t- be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear t- differ from partner t- partner or deal type t- deal type?
Which jurisdiction does the company insist upon for agreement law?
Global Public Health Partnering 2010 t- 2016 provides the reader with the following key benefits:
In-depth understanding of Public Health deal trends since 2010
Access Public Health deal headline, upfront, milestone and royalty data
Research hundreds of actual contracts between Public Health partner companies
Comprehensive access t- over 750 links t- actual Public Health deals entered int- by the world’s biopharma companies
Indepth review of Public Health deals entered int- by the top 25 most active dealmakers
Benchmark the key deal terms companies have agreed in previous deals
Identify key terms under which companies partner Public Health opportunities
Uncover companies actively partnering Public Health opportunities